Disease progression and costs at the 3‐year follow‐up of the GERAS‐US study
Abstract Introduction GERAS‐US prospectively characterized clinical and economic outcomes of early symptomatic Alzheimer's disease (AD). Societal cost changes were examined in amyloid‐positive patients with mild cognitive impairment due to AD (MCI) and mild dementia due to AD (MILD). Methods Co...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-04-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.12430 |